Psychstocks believes there is only one publicly traded company that is well-positioned to capitalize on rapidly growing interest in DMT and Ayahuasca: Entheon Biomedical (CSE: ENBI), which also trades on the U.S. OTC under the symbol ENTBF.
BetterLife Files Patent for the Treatment of MDD Utilizing its Second-Generation Psychedelic Derivative for 2-Bromo-LSD
BetterLife Pharma (CSE: BETR) has announced this morning that it has applied for patent protection of its new 2-Bromo-LSD formulation TD-0148A and its use in the treatment of Major Depressive Disorder (MDD). BETR is beginning its pre-clinical work on TD-0148A in preparation for a Pre-IND Meeting with the FDA in March, which will allow BETR to file its IND to launch clinical trials of TD-0148A for the treatment of MDD later this year!
On the afternoon of December 18th, Psychstocks announced BetterLife Pharma (CSE: BETR) at $1.17 per share as its #1 favorite Psychstock for 2021. BETR closed today at its high of day of $2.25 per share. BETR has already gained by 92.3% in only seven trading days!
BETR is truly establishing the best possible team to take LSD and other psychedelics from experimental to major therapeutic applications.
Numinus Wellness (TSXV: NUMI) gained as much as 9.87% today to hit a new all-time high of $2.45 per share for a gain of 807.41% since we profiled it as our #1 favorite Psychstock at $0.27 per share!
Psychstocks founder Gerard Adams considers RVV and NUMI to be the two highest quality small-cap stocks in the psychedelic space and their incredibly strong performance is proving Gerard right!
NUMI is pleased about first-of-its-kind policy amendment that will allow legal access to evidence-based treatments to those in need before formal drug approval.
Numinus Wellness (TSXV: NUMI) had its biggest up day in history on Wednesday gaining by 34.83% to finish at a new all-time high closing price of $1.20 per share.
NUMI and MAPS Public Benefit Corporation Announce Collaboration Agreement to Seek Approval of MDMA-Assisted Psychotherapy for PTSD
This is perhaps NUMI’s most significant development in its history.
Psychedelics industry bellwether Compass Pathways (CMPS) gained $6.62 or 16.21% today to finish at a new all-time high closing price of $47.45 per share! We consider Revive Therapeutics (CSE: RVV) to be the #1 highest quality small-cap psychedelic biotech play.
RVV provides important update on its oral thin-film delivery system with psilocybin being developed under a research partnership agreement with Reed Research Group out of the University of Wisconsin-Madison.
Oregon residents voted to pass Measure 109 to legalize psilocybin from mushrooms while Washington DC residents voted to pass Initiative 81 to decriminalize natural plant medicines.